Literature DB >> 31573721

Blood eosinophils could be useful as a biomarker in chronic obstructive pulmonary disease exacerbations.

Francisco-Javier Gonzalez-Barcala1,2,3,4, Maria-Esther San-Jose5, Juan-José Nieto-Fontarigo6, Uxio Calvo-Alvarez7, Jose-Martín Carreira8, Maria-Teresa Garcia-Sanz9, Xavier Muñoz2,10, Maria-Purificacion Perez-Lopez-Corona3, Maria-Jose Gómez-Conde5, Alejandro Casas-Fernández5, Luis Valdes-Cuadrado1,3,4, Lara Mateo-Mosquera3, Francisco-Javier Salgado6.   

Abstract

Introduction The aim of analysing the usefulness of the blood eosinophil count (BEC) as a prognostic marker in exacerbations of patients with Chronic Obstructive Pulmonary Disease (COPD), evaluating its relationship with hospital mortality, the length of stay and the early and late re-admissions. Materials and Methods We have carried out a retrospective study including all patients who required hospital admission from 1 January 2008 to 31 December 2009, with a diagnosis on hospital discharge of COPD exacerbation. These patients were classified using three cut-off points of BEC: less than 200 vs ≥ 200/µL, less than 300 vs ≥ 300/µL and less than 400 vs ≥ 400/µL. Results There were a total of 1626 hospital admissions during the study period with the diagnosis of exacerbation of COPD. In this study we have included 358 patients. The probability of any late re-admission increased with a BEC ≥ 300/µL (odds ratio: 1.684) and for those with a BEC ≥ 400/µL (odds ratio: 2.068). The BEC does not appear to be related to hospital mortality or the probability of early re-admission after an exacerbation of COPD. Conclusions In our study an elevated BEC is associated with a higher incidence of late hospital readmissions in COPD exacerbations.
© 2019 John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 31573721     DOI: 10.1111/ijcp.13423

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  7 in total

1.  Factors Associated with Treatment Failure in Patients with Acute Exacerbation of COPD Admitted to the Emergency Department Observation Unit.

Authors:  Wasuntaraporn Pethyabarn; Sareeman Chewae; Ar-Aishah Dadeh
Journal:  Emerg Med Int       Date:  2020-06-29       Impact factor: 1.112

2.  Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study.

Authors:  Yanan Cui; Wenye Zhang; Yiming Ma; Zijie Zhan; Yan Chen
Journal:  Respir Res       Date:  2021-11-24

3.  Blood Eosinophils and Clinical Outcomes in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Propensity Score Matching Analysis of Real-World Data in China.

Authors:  Yanan Cui; Zijie Zhan; Zihang Zeng; Ke Huang; Chen Liang; Xihua Mao; Yaowen Zhang; Xiaoxia Ren; Ting Yang; Yan Chen
Journal:  Front Med (Lausanne)       Date:  2021-06-09

4.  Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Tao Liu; Zi-Jian Xiang; Xiao-Meng Hou; Jing-Jing Chai; Yan-Li Yang; Xiao-Tong Zhang
Journal:  Ther Adv Chronic Dis       Date:  2021-07-07       Impact factor: 5.091

5.  Elevated blood eosinophils in acute COPD exacerbations: better short- and long-term prognosis.

Authors:  Ajmal Jabarkhil; Mia Moberg; Julie Janner; Mie Nymann Petersen; Camilla Bjørn Jensen; Lars Henrik Äangquist; Jørgen Vestbo; Tine Jess; Celeste Porsbjerg
Journal:  Eur Clin Respir J       Date:  2020-04-30

6.  Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain.

Authors:  Bernardino Alcázar-Navarrete; Francisco García-Rio; Guadalupe Sánchez; Esther Mariscal; Andrea García; Maribel Cuesta; Estefany Uría; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-07-21

7.  Variability of blood eosinophil count and prognosis of COPD exacerbations.

Authors:  Sandra Martínez-Gestoso; María-Teresa García-Sanz; Uxío Calvo-Álvarez; Liliana Doval-Oubiña; Sandra Camba-Matos; Francisco-Javier Salgado; Xavier Muñoz; Purificación Perez-Lopez-Corona; Francisco-Javier González-Barcala
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.